A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Brief description of study

The current study is being conducted to evaluate the MRD negativity conversion rate following the addition of daratumumab to lenalidomide, when administered as maintenance treatment to patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplant (ASCT). This study is for patients who have received 4 to 8 cycles of induction with or without consolidation, have undergone HDT and ASCT, are MRD positive, and have never been treated with an anti-CD38 antibody (ie, are anti-CD38 naïve).




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.